These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22504727)

  • 1. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
    Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Katsuki A; Umene-Nakano W; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):355-7. PubMed ID: 22813840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
    Nakajima S; Uchida H; Suzuki T; Watanabe K; Hirano J; Yagihashi T; Takeuchi H; Abe T; Kashima H; Mimura M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1983-9. PubMed ID: 21889560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
    Connolly KR; Helmer A; Cristancho MA; Cristancho P; O'Reardon JP
    J Clin Psychiatry; 2012 Apr; 73(4):e567-73. PubMed ID: 22579164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant response in the elderly.
    Mandelli L; Serretti A; Zanardi R; Rossini D; De Ronchi D; Tarricone I; Colombo C
    Psychiatry Res; 2007 Jul; 152(1):37-44. PubMed ID: 17383015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
    Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.